TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07447102: A Phase II Clinical Study to Evaluate the Efficacy and Safety of BC006 in Patients With Idiopathic Pulmonary Fibrosis

Sponsor: Dragonboat Biopharmaceutical Company Limited · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 96 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07447102 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07447102 Rescue Dossier →